Two marketed ADCs are based on the monoclonal antibody Trastuzumab targeting the human epidermal growth factor receptor 2 (HER2), a well-studied tumor antigen overexpressed in a variety of malignant diseases, including breast cancer (129, 130) and lung cancer (131, 132). This evidence concerns the gene ERBB2 and neoplasm.